Previous Close | 37.63 |
Open | 37.33 |
Bid | 37.07 x 1300 |
Ask | 37.24 x 900 |
Day's Range | 35.89 - 37.64 |
52 Week Range | 19.23 - 49.24 |
Volume | |
Avg. Volume | 359,840 |
Market Cap | 1.435B |
Beta (5Y Monthly) | 1.26 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.58 |
Earnings Date | May 02, 2023 - May 08, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 63.38 |
Today is shaping up negative for Morphic Holding, Inc. ( NASDAQ:MORF ) shareholders, with the analysts delivering a...
WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the TD Cowen 43rd Annual Health Care Conference. Presentation Information GI/Microbiome Panel Discussion9:10 AM E
Morphic Holding ( NASDAQ:MORF ) Full Year 2022 Results Key Financial Results Revenue: US$70.8m (up 258% from FY 2021...